Monday, May 4, 2009
MONDAY, May 4 (HealthDay News) -- Two novel drug-delivery techniques show promise in the treatment of malignant gliomas, according to two studies presented at the annual meeting of the American Association of Neurological Surgeons, held from May 2 to 6 in San Diego.
In one study, Jeffrey N. Bruce, M.D., of the Columbia University Medical Center in New York City, and colleagues used convection enhanced delivery to administer 40 milliliters of topotecan directly into the brains of 16 patients over a 100-hour period. They found that the lowest infusion dose concentration -- less than 0.1 mg/mL -- had no toxic effects. After six months, they found that overall survival was 77 percent and that tumors had regressed in many patients.
In a second study, Jason P. Sheehan, M.D., of the University of Virginia in Charlottesville, and colleagues injected controlled-release nanoparticles containing fluorouracil (5-FU) into mice with an animal model of glioma. They found that the nanoparticles were able to pass through the blood-brain barrier, release the fluorouracil, and reduce tumor cell viability.
"This Phase I study provides information that allowed us to establish the maximum tolerated dose of topotecan," Bruce and colleagues conclude. "Results are encouraging as tumor regression was seen in this study at drug concentrations lower than the maximum tolerated dose. A multicenter Phase II study is planned using the maximum tolerated dose to determine treatment efficacy."
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.